全文获取类型
收费全文 | 8480篇 |
免费 | 508篇 |
国内免费 | 114篇 |
专业分类
耳鼻咽喉 | 125篇 |
儿科学 | 150篇 |
妇产科学 | 81篇 |
基础医学 | 1409篇 |
口腔科学 | 145篇 |
临床医学 | 693篇 |
内科学 | 1752篇 |
皮肤病学 | 476篇 |
神经病学 | 623篇 |
特种医学 | 518篇 |
外科学 | 1037篇 |
综合类 | 20篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 308篇 |
眼科学 | 190篇 |
药学 | 837篇 |
中国医学 | 143篇 |
肿瘤学 | 593篇 |
出版年
2024年 | 5篇 |
2023年 | 54篇 |
2022年 | 177篇 |
2021年 | 349篇 |
2020年 | 180篇 |
2019年 | 241篇 |
2018年 | 287篇 |
2017年 | 235篇 |
2016年 | 327篇 |
2015年 | 408篇 |
2014年 | 518篇 |
2013年 | 494篇 |
2012年 | 807篇 |
2011年 | 786篇 |
2010年 | 407篇 |
2009年 | 377篇 |
2008年 | 507篇 |
2007年 | 432篇 |
2006年 | 352篇 |
2005年 | 389篇 |
2004年 | 270篇 |
2003年 | 229篇 |
2002年 | 226篇 |
2001年 | 175篇 |
2000年 | 184篇 |
1999年 | 130篇 |
1998年 | 48篇 |
1997年 | 27篇 |
1996年 | 35篇 |
1995年 | 15篇 |
1994年 | 32篇 |
1993年 | 16篇 |
1992年 | 41篇 |
1991年 | 44篇 |
1990年 | 37篇 |
1989年 | 49篇 |
1988年 | 28篇 |
1987年 | 30篇 |
1986年 | 25篇 |
1985年 | 22篇 |
1984年 | 10篇 |
1983年 | 6篇 |
1981年 | 9篇 |
1980年 | 14篇 |
1979年 | 15篇 |
1978年 | 7篇 |
1977年 | 9篇 |
1971年 | 4篇 |
1970年 | 4篇 |
1967年 | 4篇 |
排序方式: 共有9102条查询结果,搜索用时 15 毫秒
1.
2.
3.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献4.
5.
Clinical usefulness of intraductal ultrasonography for the management of acute biliary pancreatitis
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
6.
7.
8.
K.-C. Sung D.-C. Seo S.-J. Lee M.-Y. Lee S.H. Wild C.D. Byrne 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2019,29(5):489-495
Background and aims
It is not known whether non alcoholic fatty liver disease (NAFLD) is a risk factor for diabetes in non obese, non centrally-obese subjects. Our aim was to investigate relationships between fatty liver, insulin resistance and a biomarker score for liver fibrosis with incident diabetes at follow up, in subjects who were neither obese nor centrally-obese.Methods and results
As many as 70,303 subjects with a body mass index (BMI) < 25 kg/m2 and without diabetes were followed up for a maximum of 7.9 years. At baseline, fatty liver was identified by liver ultrasound, insulin resistance (IR) by homeostatic model assessment of insulin resistance (HOMA-IR) ≥2.0, and central obesity by waist circumference (waist circumference ≥90 cm (men) and ≥85 cm (women). The Fibrosis-4 (FIB-4 score) was used to estimate extent of liver fibrosis. Cox proportional hazards models adjusted for confounders were used to estimate hazard ratios (aHRs) for incident diabetes. As many as 852 incident cases of diabetes occurred during follow up (median [IQR] 3.71 [2.03] years). Mean ± SD BMI was 22.8 ± 1.8 and 21.7 ± 2.0 kg/m2 in subjects with and without diabetes at follow up. In subjects without central obesity and with fatty liver, aHRs (95% CI) for incident diabetes at follow up were 2.17 (1.56, 3.03) for men, and 2.86 (1.50,5.46) for women. Similar aHRs for incident diabetes occurred with fatty liver, IR and the highest quartile of FIB-4 combined, in men; and there was a non significant trend toward increased risk in women.Conclusions
In normal weight, non-centrally obese subjects NAFLD is an independent risk factor for incident diabetes. 相似文献9.
Xiaoqing Guo Ji-Eun Seo Xilin Li Nan Mei 《Journal of toxicology and environmental health. Part B, Critical reviews》2020,23(1):27-50
ABSTRACTGenotoxic compounds may be detoxified to non-genotoxic metabolites while many pro-carcinogens require metabolic activation to exert their genotoxicity in vivo. Standard genotoxicity assays were developed and utilized for risk assessment for over 40 years. Most of these assays are conducted in metabolically incompetent rodent or human cell lines. Deficient in normal metabolism and relying on exogenous metabolic activation systems, the current in vitro genotoxicity assays often have yielded high false positive rates, which trigger unnecessary and costly in vivo studies. Metabolically active cells such as hepatocytes have been recognized as a promising cell model in predicting genotoxicity of carcinogens in vivo. In recent years, significant advances in tissue culture and biological technologies provided new opportunities for using hepatocytes in genetic toxicology. This review encompasses published studies (both in vitro and in vivo) using hepatocytes for genotoxicity assessment. Findings from both standard and newly developed genotoxicity assays are summarized. Various liver cell models used for genotoxicity assessment are described, including the potential application of advanced liver cell models such as 3D spheroids, organoids, and engineered hepatocytes. An integrated strategy, that includes the use of human-based cells with enhanced biological relevance and throughput, and applying the quantitative analysis of data, may provide an approach for future genotoxicity risk assessment. 相似文献
10.